Briefs, Companies,

T2S Group starts building a radiopharmaceutical plant in Fez

Through its subsidiary Cyclopharma, T2S Group has started building a plant in Fez to produce radiopharmaceutical drugs. The investment is estimated at MAD 60 million, with start-up planned for the second quarter of 2028.

T2S Group has announced the start of construction, in Fez, of a new plant producing radiopharmaceutical drugs, which are used in nuclear medicine. The project is led by its subsidiary Cyclopharma. Work began on 1 October 2026.

The investment is estimated at MAD 60 million, according to Médias24. The site will include a bunker for a cyclotron, the machine that produces radioisotopes, as well as production and quality-control laboratories.

It will complement the plant Cyclopharma already runs in Bouskoura-Oulad Saleh, near Casablanca, and is meant to improve coverage of the Fez-Meknes and Oriental regions. Start-up is scheduled for the second quarter of 2028, subject to progress on the works and regulatory approvals.

Read the profile of T2S Group

Sources: T2S Group, communiqué : lancement à Fès de la construction d'une nouvelle unité de production de médicaments radiopharmaceutiques (via Médias24), November 9, 2026; Médias24, T2S Group investit 60 MDH dans une nouvelle unité de médicaments radiopharmaceutiques à Fès, November 10, 2026.

General information only. Nothing on this site constitutes investment advice or a recommendation to buy or sell.